An ILC, or innate lymphoid cell, is a type of immune cell that guards your body’s barrier surfaces, including the gut lining, lungs, and skin. Unlike the better-known T cells and B cells, ILCs lack the specialized receptors that recognize specific pathogens. Instead, they respond rapidly to chemical alarm signals from damaged or infected tissue, acting as a fast-response team while the rest of your immune system gears up for a more targeted attack.
ILCs were formally named and classified in 2013, though scientists had been discovering different subsets since the late 1990s. Between 2008 and 2009 alone, twelve independent research groups reported finding new types of these cells in mammals. Since then, ILCs have become one of the most active areas of immunology research because of their outsized role in allergies, gut health, and even metabolism.
Where ILCs Live in Your Body
ILCs are primarily tissue-resident cells, meaning they stay put in the organs where they work rather than circulating through your bloodstream. They’re extremely rare in blood but abundant at mucosal surfaces: the moist linings of your intestines, airways, mouth, and gums. These are the places where your body is most exposed to the outside world, whether that’s food, airborne particles, or bacteria.
Different parts of the digestive tract house different ILC populations. The upper GI tract, including the esophagus, is enriched with one subtype (ILC1s), while the lower intestine and colon are dominated by another (ILC3s). ILCs also populate the entire respiratory tract and have been found in tonsils, gum tissue, and lymph nodes.
The Three Main Types
ILCs come in three major groups, each mirroring a corresponding type of T helper cell. Think of them as the innate immune system’s version of the same playbook your adaptive immune system uses, just faster and less precise.
- ILC1s are the counterpart of Th1 cells. They specialize in fighting viruses and certain bacteria by producing interferon-gamma and tumor necrosis factor-alpha, signaling molecules that ramp up inflammation to kill infected cells. They depend on a signal called IL-15 to develop and function normally. Unlike natural killer cells, which they closely resemble, ILC1s generally can’t directly kill target cells.
- ILC2s mirror Th2 cells. They respond to parasitic worms and allergens by pumping out IL-5 and IL-13, which recruit specialized white blood cells called eosinophils and stimulate mucus production. ILC2s are activated by alarm signals (called alarmins) released from damaged epithelial cells, particularly IL-33, IL-25, and TSLP.
- ILC3s correspond to Th17 cells. They produce IL-22 and IL-17, which help maintain the intestinal barrier and fight bacterial and fungal infections. ILC3s are the most abundant ILC subset in both the fetal and adult human intestine.
How ILCs Get Activated
Your adaptive immune system needs days to mount a full response because T and B cells must first recognize a specific pathogen, then multiply. ILCs skip that step entirely. They don’t need to identify a particular invader. Instead, they’re activated by distress signals from the tissue around them.
When epithelial cells (the cells lining your gut, airways, or skin) are damaged by infection, toxins, or allergens, they release alarmins. These molecules act like a fire alarm, and ILCs are the first responders. ILC2s, for example, pick up IL-33 and IL-25 through dedicated receptors on their surface and immediately begin secreting cytokines that coordinate the broader immune response. This speed is what makes ILCs essential at barrier surfaces, where threats arrive constantly and waiting days for T cells isn’t an option.
ILC3s and Gut Health
ILC3s play a particularly important role in keeping your intestines healthy. Their signature product, IL-22, acts directly on the cells lining the gut to strengthen the barrier in several ways. It triggers the production of mucins, the proteins that form the protective mucus layer coating your intestinal walls. It also increases the number of goblet cells, which are the specialized cells responsible for making that mucus.
IL-22 stimulates another critical defense: antimicrobial proteins. Specialized cells in the small intestine called Paneth cells produce these proteins to kill harmful bacteria, and IL-22 is one of the key signals telling them to ramp up production. On top of that, IL-22 helps regulate tight junctions between epithelial cells, controlling the permeability of the intestinal lining. It can even activate part of the complement system, an ancient bacterial-killing mechanism, in both the gut and the liver to prevent bacteria from spreading into the bloodstream.
This makes ILC3 dysfunction relevant to conditions like Crohn’s disease. IL-22 induces a gene called FUT2 in intestinal cells, and genetic variants of FUT2 have been implicated in Crohn’s disease risk.
ILC2s in Asthma and Allergies
The same ILC2 responses that protect against parasitic worms can cause serious problems when they misfire. In allergic asthma, airway ILC2s expand in number and flood the lungs with IL-5 and IL-13. IL-5 acts as a powerful recruitment signal for eosinophils, pulling them from the bone marrow into the airways. The concentration of IL-5 in airway fluid directly correlates with the degree of eosinophil buildup. IL-13, meanwhile, drives mucus overproduction and structural changes in the airway walls known as remodeling.
This cascade makes ILC2s key drivers of airway inflammation in asthma, particularly in children. Because ILC2s respond to epithelial alarm signals rather than specific allergens, they can initiate and amplify allergic inflammation even before T cells get involved. This helps explain why some people develop asthma symptoms rapidly upon exposure to triggers.
ILCs and Body Fat
One of the more surprising discoveries about ILCs is their role in metabolism. ILC2s have been found in human white adipose tissue (body fat), and their numbers are notably reduced in people with obesity. In animal studies, IL-33 maintains ILC2 populations in fat tissue and helps limit weight gain by increasing caloric expenditure.
The mechanism involves a process called beiging, where white fat cells take on characteristics of calorie-burning brown fat cells by producing a protein called UCP1. ILC2s drive this conversion by releasing small peptides called methionine-enkephalins, which act directly on fat cells to switch on UCP1 production. Transferring ILC2s into mice was enough to promote beiging on its own, independent of T cells, B cells, or eosinophils. This effect was specific to white fat and didn’t occur in brown fat, which already burns calories at a high rate.
These findings position ILC2s as a link between the immune system and metabolic regulation, suggesting that immune health in fat tissue may influence how efficiently your body burns energy.